Literature DB >> 9525450

The utility of methacholine airway responsiveness measurements in evaluating anti-asthma drugs.

M D Inman1, A L Hamilton, H A Kerstjens, R M Watson, P M O'Byrne.   

Abstract

BACKGROUND: Measurements of airway responsiveness are frequently used to evaluate anti-asthma drugs.
OBJECTIVE: This study investigated the utility of methacholine airway responsiveness measurements in evaluating anti-asthma medications, both in terms of a bronchoprotective effect and the ability to attenuate allergen-induced methacholine airway hyperresponsiveness.
METHODS: Methacholine airway responsiveness was measured as PC20 on two occasions (separated by 35+/-17 days, mean +/- SD) in 40 subjects with mild, stable asthma. Additional subjects had PC20 measurements made before and after administration of either inhaled salbutamol (200 microg) (n = 20) or allergen inhalation challenge (n = 31).
RESULTS: The reproducibility of the methacholine PC20 with this method was high (intraclass correlation coefficient = 0.94). The average shift in PC20 after salbutamol was 4.11 doubling concentrations (SD = 1.08). On the basis of these results, a sample size of 12 subjects would be required to demonstrate a 1 doubling concentration difference in the bronchoprotective effect of two drugs with a 90% power. The average shift in PC20 after allergen was 1.29 doubling concentrations. On the basis of these results and an estimated SD of 0.96, a sample size of 24 subjects would be required to demonstrate that a drug is effective in attenuating 50% of allergen-induced airway hyperresponsiveness with a 90% power.
CONCLUSION: These results confirm the high reproducibility of methacholine PC20 measurements in subjects with mild, stable asthma and demonstrate its utility in evaluating the effects of anti-asthma drugs.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9525450     DOI: 10.1016/S0091-6749(98)70246-5

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  5 in total

1.  The arginine-16 beta2-adrenoceptor polymorphism predisposes to bronchoprotective subsensitivity in patients treated with formoterol and salmeterol.

Authors:  Daniel K C Lee; Graeme P Currie; Ian P Hall; John J Lima; Brian J Lipworth
Journal:  Br J Clin Pharmacol       Date:  2004-01       Impact factor: 4.335

2.  Comparison of bronchoprotective and bronchodilator effects of a single dose of formoterol delivered by hydrofluoroalkane and chlorofluorocarbon aerosols and dry powder in a double blind, placebo-controlled, crossover study.

Authors:  C M Houghton; S J Langley; S D Singh; J Holden; A P Monici Preti; D Acerbi; G Poli; A Woodcock
Journal:  Br J Clin Pharmacol       Date:  2004-10       Impact factor: 4.335

3.  Comparing the effects of two inhaled glucocorticoids on allergen-induced bronchoconstriction and markers of systemic effects, a randomised cross-over double-blind study.

Authors:  Jan Lötvall; Mona Palmqvist; Peter Arvidsson
Journal:  Clin Transl Allergy       Date:  2011-10-31       Impact factor: 5.871

4.  Clinical Implications of Oscillatory Lung Function during Methacholine Bronchoprovocation Testing of Preschool Children.

Authors:  Sun Hee Choi; Youn Ho Sheen; Mi Ae Kim; Ji Hyeon Baek; Hey Sung Baek; Seung Jin Lee; Jung Won Yoon; Yeong Ho Rha; Man Yong Han
Journal:  Biomed Res Int       Date:  2017-06-27       Impact factor: 3.411

5.  Effect of Study Design on Sample Size in Studies Intended to Evaluate Bioequivalence of Inhaled Short-Acting β-Agonist Formulations.

Authors:  Yaohui Zeng; Sachinkumar Singh; Kai Wang; Richard C Ahrens
Journal:  J Clin Pharmacol       Date:  2017-12-27       Impact factor: 3.126

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.